Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans
A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two diffe...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 1978-12, Vol.67 (12), p.1659-1661 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1661 |
|---|---|
| container_issue | 12 |
| container_start_page | 1659 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 67 |
| creator | Meyer, Marvin C. Straughn, Arthur B. Ramachander, Gollamudi Cavagnol, Jerry C. Biola Mabadeje, A.F. |
| description | A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets. All dosage forms were equivalent to 500mg of sulfadiazine. Blood samples were obtained at 0,0.5,1.0, 2.0, 3.0, 4.0,6.0,8.0,10.0, 25.0,33.0, and 49.0hr. Analysis of variance indicated no statistically significant difference (p>0.05) between the dosage forms in terms of area under the plasma level-time curve, peak plasma concentration, and time of peak plasma concentration. In both groups, there were differences between products at isolated sampling times. It was concluded that the four tablet formulations of sulfadiazine exhibited bioavailability characteristics equivalent to those of the solution and the suspension. |
| doi_str_mv | 10.1002/jps.2600671205 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74275925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915423615</els_id><sourcerecordid>74275925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4265-284befec9403ad6fd4b210ce0802e15fbfd838c0ddfedf19ca8612b151fd686d3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1Ege3ClROHnDg127ETO86RVv2gXb60izhajj2WvHiTJU4Ky6_HVVZFPSBOI8887yv5IeQ1hQUFYKebXVwwASAqyoA_ITPKGeQCaPWUzBLA8oKX9QtyHOMGEgacPyfPuKRlLWfkw5nv9J32QTc--GGfdS5bjcFp6_Vv32K26sI4-K6NJ2kfd9jG6aFbm611E3CImW-z63Gr2_iSHDkdIr46zDn5enmxPr_Ol5-u3p-_W-amZILnTJYNOjR1CYW2wtmyYRQMggSGlLvGWVlIA9Y6tI7WRktBWUM5dVZIYYs5eTv17vrux4hxUFsfDYagW-zGqKqSVbxmPIGLCTR9F2OPTu16v9X9XlFQ9_pU0qf-6kuBN4fmsdmifcAnX-lcT-efPuD-P2Xq5vPqUXU-ZX0c8NdDVvfflaiKiqtvH6_U6uZLBZe3Z2qdeDnxmEzeeexVNB5bg9b3aAZlO_-vX_wBWpuelw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74275925</pqid></control><display><type>article</type><title>Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Meyer, Marvin C. ; Straughn, Arthur B. ; Ramachander, Gollamudi ; Cavagnol, Jerry C. ; Biola Mabadeje, A.F.</creator><creatorcontrib>Meyer, Marvin C. ; Straughn, Arthur B. ; Ramachander, Gollamudi ; Cavagnol, Jerry C. ; Biola Mabadeje, A.F.</creatorcontrib><description>A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets. All dosage forms were equivalent to 500mg of sulfadiazine. Blood samples were obtained at 0,0.5,1.0, 2.0, 3.0, 4.0,6.0,8.0,10.0, 25.0,33.0, and 49.0hr. Analysis of variance indicated no statistically significant difference (p>0.05) between the dosage forms in terms of area under the plasma level-time curve, peak plasma concentration, and time of peak plasma concentration. In both groups, there were differences between products at isolated sampling times. It was concluded that the four tablet formulations of sulfadiazine exhibited bioavailability characteristics equivalent to those of the solution and the suspension.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600671205</identifier><identifier>PMID: 581498</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>Administration, Oral ; Adult ; Antibacterials-sulfadiazine ; Antibacterials—sulfadiazine bioavailability of various dosage forms compared in humans ; bioavailability of various dosage forms compared in humans ; Bioavailability-sulfadiazine ; Bioavailability—sulfadiazine various dosage forms compared in humans ; Biological Availability ; Half-Life ; Humans ; Male ; Solutions ; Sulfadiazine - administration & dosage ; Sulfadiazine - blood ; Sulfadiazine - metabolism ; Sulfadiazine-bioavailability of various dosage forms compared in humans ; Suspensions ; Tablets ; various dosage forms compared in humans</subject><ispartof>Journal of pharmaceutical sciences, 1978-12, Vol.67 (12), p.1659-1661</ispartof><rights>1978 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1978 Wiley‐Liss, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4265-284befec9403ad6fd4b210ce0802e15fbfd838c0ddfedf19ca8612b151fd686d3</citedby><cites>FETCH-LOGICAL-c4265-284befec9403ad6fd4b210ce0802e15fbfd838c0ddfedf19ca8612b151fd686d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600671205$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600671205$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/581498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meyer, Marvin C.</creatorcontrib><creatorcontrib>Straughn, Arthur B.</creatorcontrib><creatorcontrib>Ramachander, Gollamudi</creatorcontrib><creatorcontrib>Cavagnol, Jerry C.</creatorcontrib><creatorcontrib>Biola Mabadeje, A.F.</creatorcontrib><title>Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets. All dosage forms were equivalent to 500mg of sulfadiazine. Blood samples were obtained at 0,0.5,1.0, 2.0, 3.0, 4.0,6.0,8.0,10.0, 25.0,33.0, and 49.0hr. Analysis of variance indicated no statistically significant difference (p>0.05) between the dosage forms in terms of area under the plasma level-time curve, peak plasma concentration, and time of peak plasma concentration. In both groups, there were differences between products at isolated sampling times. It was concluded that the four tablet formulations of sulfadiazine exhibited bioavailability characteristics equivalent to those of the solution and the suspension.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antibacterials-sulfadiazine</subject><subject>Antibacterials—sulfadiazine bioavailability of various dosage forms compared in humans</subject><subject>bioavailability of various dosage forms compared in humans</subject><subject>Bioavailability-sulfadiazine</subject><subject>Bioavailability—sulfadiazine various dosage forms compared in humans</subject><subject>Biological Availability</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Male</subject><subject>Solutions</subject><subject>Sulfadiazine - administration & dosage</subject><subject>Sulfadiazine - blood</subject><subject>Sulfadiazine - metabolism</subject><subject>Sulfadiazine-bioavailability of various dosage forms compared in humans</subject><subject>Suspensions</subject><subject>Tablets</subject><subject>various dosage forms compared in humans</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1Ege3ClROHnDg127ETO86RVv2gXb60izhajj2WvHiTJU4Ky6_HVVZFPSBOI8887yv5IeQ1hQUFYKebXVwwASAqyoA_ITPKGeQCaPWUzBLA8oKX9QtyHOMGEgacPyfPuKRlLWfkw5nv9J32QTc--GGfdS5bjcFp6_Vv32K26sI4-K6NJ2kfd9jG6aFbm611E3CImW-z63Gr2_iSHDkdIr46zDn5enmxPr_Ol5-u3p-_W-amZILnTJYNOjR1CYW2wtmyYRQMggSGlLvGWVlIA9Y6tI7WRktBWUM5dVZIYYs5eTv17vrux4hxUFsfDYagW-zGqKqSVbxmPIGLCTR9F2OPTu16v9X9XlFQ9_pU0qf-6kuBN4fmsdmifcAnX-lcT-efPuD-P2Xq5vPqUXU-ZX0c8NdDVvfflaiKiqtvH6_U6uZLBZe3Z2qdeDnxmEzeeexVNB5bg9b3aAZlO_-vX_wBWpuelw</recordid><startdate>197812</startdate><enddate>197812</enddate><creator>Meyer, Marvin C.</creator><creator>Straughn, Arthur B.</creator><creator>Ramachander, Gollamudi</creator><creator>Cavagnol, Jerry C.</creator><creator>Biola Mabadeje, A.F.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197812</creationdate><title>Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans</title><author>Meyer, Marvin C. ; Straughn, Arthur B. ; Ramachander, Gollamudi ; Cavagnol, Jerry C. ; Biola Mabadeje, A.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4265-284befec9403ad6fd4b210ce0802e15fbfd838c0ddfedf19ca8612b151fd686d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antibacterials-sulfadiazine</topic><topic>Antibacterials—sulfadiazine bioavailability of various dosage forms compared in humans</topic><topic>bioavailability of various dosage forms compared in humans</topic><topic>Bioavailability-sulfadiazine</topic><topic>Bioavailability—sulfadiazine various dosage forms compared in humans</topic><topic>Biological Availability</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Male</topic><topic>Solutions</topic><topic>Sulfadiazine - administration & dosage</topic><topic>Sulfadiazine - blood</topic><topic>Sulfadiazine - metabolism</topic><topic>Sulfadiazine-bioavailability of various dosage forms compared in humans</topic><topic>Suspensions</topic><topic>Tablets</topic><topic>various dosage forms compared in humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, Marvin C.</creatorcontrib><creatorcontrib>Straughn, Arthur B.</creatorcontrib><creatorcontrib>Ramachander, Gollamudi</creatorcontrib><creatorcontrib>Cavagnol, Jerry C.</creatorcontrib><creatorcontrib>Biola Mabadeje, A.F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, Marvin C.</au><au>Straughn, Arthur B.</au><au>Ramachander, Gollamudi</au><au>Cavagnol, Jerry C.</au><au>Biola Mabadeje, A.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1978-12</date><risdate>1978</risdate><volume>67</volume><issue>12</issue><spage>1659</spage><epage>1661</epage><pages>1659-1661</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets. All dosage forms were equivalent to 500mg of sulfadiazine. Blood samples were obtained at 0,0.5,1.0, 2.0, 3.0, 4.0,6.0,8.0,10.0, 25.0,33.0, and 49.0hr. Analysis of variance indicated no statistically significant difference (p>0.05) between the dosage forms in terms of area under the plasma level-time curve, peak plasma concentration, and time of peak plasma concentration. In both groups, there were differences between products at isolated sampling times. It was concluded that the four tablet formulations of sulfadiazine exhibited bioavailability characteristics equivalent to those of the solution and the suspension.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>581498</pmid><doi>10.1002/jps.2600671205</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 1978-12, Vol.67 (12), p.1659-1661 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_74275925 |
| source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Administration, Oral Adult Antibacterials-sulfadiazine Antibacterials—sulfadiazine bioavailability of various dosage forms compared in humans bioavailability of various dosage forms compared in humans Bioavailability-sulfadiazine Bioavailability—sulfadiazine various dosage forms compared in humans Biological Availability Half-Life Humans Male Solutions Sulfadiazine - administration & dosage Sulfadiazine - blood Sulfadiazine - metabolism Sulfadiazine-bioavailability of various dosage forms compared in humans Suspensions Tablets various dosage forms compared in humans |
| title | Bioavailability of Sulfadiazine Solutions, Suspensions, and Tablets in Humans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioavailability%20of%20Sulfadiazine%20Solutions,%20Suspensions,%20and%20Tablets%20in%20Humans&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Meyer,%20Marvin%20C.&rft.date=1978-12&rft.volume=67&rft.issue=12&rft.spage=1659&rft.epage=1661&rft.pages=1659-1661&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1002/jps.2600671205&rft_dat=%3Cproquest_cross%3E74275925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74275925&rft_id=info:pmid/581498&rft_els_id=S0022354915423615&rfr_iscdi=true |